BCRX compared with MNPR: revenue, margins and what each company keeps, and the suppliers and customers both name

BCRXBiocryst Pharmaceuticals Inc

Mkt capRevenueRevenue

MNPRMonopar Therapeutics

Mkt capRevenueRevenue

Compare

BCRXBiocryst Pharmaceuticals Inc

MNPRMonopar Therapeutics

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

BCRX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±10.0%▲+0.55%×0.06

May 6 '26±8.9%▼−2.21%×0.25

Q1 FY26±7.0%▲+4.64%×0.66

Jan 13 '26±7.9%▼−4.80%×0.61

MNPR

Reportimpliedrealized× implied

Q2 FY26—▲+0.38%—

May 14 '26—▼−0.73%—

Q1 FY26

= impliedBCRX realized, solidMNPR realized, hatchedOne scale, both sides: full bar = 11%× = |realized| ÷ impliedSource: market data

—

▼−0.84%

—

Q3 FY25—▲+5.36%—

BCRXBiocryst Pharmaceuticals Inc

8.25▼−2.55%· post 8.25· delayed

Mkt cap$2.2BRevenue$218MQ2 FY26Revenue$875MFY25

MNPRMonopar Therapeutics

66.46▼−5.49%· post 66.45· delayed

After hoursNov 2 '26delayed

Mkt cap$472.0MRevenue—Revenue—

Compare

After hoursNov 2 '26delayed

BCRXBiocryst Pharmaceuticals Inc

MNPRMonopar Therapeutics

8.25▼−2.55%post 8.25delayed

Price

66.46▼−5.49%post 66.45delayed

$2.2B

Mkt cap

$472.0M

Q2 FY26$218M

Revenue

—

FY25$875M

Revenue

—

BCRX8.25▼−2.55%vsMNPR66.46▼−5.49%After hoursNov 2 '26delayed